Testing a new lung treatment for idiopathic pulmonary fibrosis

This trial is testing whether a medication called BI 765423 can help improve lung function in people with idiopathic pulmonary fibrosis (IPF), a disease where lung tissue becomes scarred and stiff over time. Half of the participants will receive BI 765423 through an IV infusion every four weeks, while the other half will receive a placebo (a fake treatment that looks identical but contains no medicine). Doctors will measure changes in lung capacity and other health markers over 3 to 6 months to see if the medication works better than placebo.

Idiopathic pulmonary fibrosis is a serious condition that gradually worsens and limits how much oxygen the lungs can process. Current treatments help slow the disease, but there is a need for new options that might work better or offer additional benefit to patients.